Hologic Contract With Consorta Expanded to Include Digital Radiography Products

Hologic Inc. (NASDAQ: HOLX), a leading provider of specialized medical imaging equipment, has been awarded an expansion of its existing contract with Consorta, Catholic Resource Partners to cover purchase and sale of Hologic digital radiography products. Consorta and Hologic originally entered into a two-year contract in October 2000 covering Hologic's radiographic and Lorad mammographic product lines.

"We are pleased to have the opportunity to expand our product offerings to Consorta to include Hologic's full array of digital radiography, general radiography, and mammographic products," said Jack Cumming, President and CEO of Hologic. "We look forward to working with Consorta to help meet their diverse needs in imaging equipment and to further developing this mutually beneficial relationship."

Consorta, Inc., based in suburban Chicago, is a leading healthcare resource management and group purchasing organization, whose shareholders are Catholic-sponsored, faith-based or non-profit health systems.

According to Pam Parker, director of group buys and imaging for Consorta, "The agreement with Hologic provides a range of high-quality medical imaging equipment to our participating facilities. We are confident that this agreement will be rewarding and successful for both parties."

Consorta's shareholder health care systems operate more than half of all Catholic hospitals in the United States, own many extended and alternate care sites and have affiliate relationships with other non-profit hospitals and alternate care facilities as well. The Consorta membership encompasses over 400 acute care facilities, representing 54,600 beds, and more than 1,700 alternate care sites. For more information visit

Hologic, Inc. is dedicated to developing and delivering proprietary X-ray and ultrasound systems that incorporate direct-to-digital radiographic imaging technology for both women's health and general radiographic applications. Hologic's business divisions include: the Hologic Radiographic Systems division encompassing general and digital radiography systems; Direct Radiography Corp., a wholly owned subsidiary and manufacturer of state-of-the- art proprietary flat panel technology called DirectRay®; the Hologic Bone Densitometry division; the LORAD division, a wholly-owned subsidiary specializing in state-of-the-art breast imaging and minimally invasive breast biopsy systems; and Fluoroscan Imaging, a wholly owned subsidiary, manufacturing and marketing state-of-the-art, low intensity, real time X-ray imaging devices.

For more information on Hologic, please visit the Company's website at

Forward-Looking Information Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's and Consorta's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated benefits from Hologic's alliance with Consorta. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's continuing losses and ability to fund those losses as well as other working capital requirements; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the early stage of market development for digital X-ray products; risks relating to the Company's reliance on a single source of supply for some key components of its products; risks related to ongoing litigation; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.


SOURCE: Hologic Inc.

Contact: Glenn P. Muir, Executive Vice President & CFO, or Marianne E. Ritchie, Manager, Investor Relations, of Hologic, Inc., +1-781-999-7300

Web site: